# Open Label Extension Study of Romiplostim (AMG 531) in Thrombocytopenic Patients With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)

> **NCT00116688** · PHASE3 · COMPLETED · sponsor: **Amgen** · enrollment: 313 (actual)

## Conditions studied

- Thrombocytopenia
- Idiopathic Thrombocytopenic Purpura

## Interventions

- **BIOLOGICAL:** Romiplostim

## Key facts

- **NCT ID:** NCT00116688
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-08
- **Primary completion:** 2010-01
- **Final completion:** 2010-01
- **Target enrollment:** 313 (ACTUAL)
- **Last updated:** 2013-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00116688

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00116688, "Open Label Extension Study of Romiplostim (AMG 531) in Thrombocytopenic Patients With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00116688. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*